Statins reduce cardiovascular morbidity and mortality with dyslipidemia.Although generally well-tolerated,dose-dependent adverse events develop in 10％-15％ patients.In addition,up to 3％ patients have mildly elevated serum aminotransferase levels within the 1st year of therapy that are rarely associated with symptoms.We report a case of clinically significant hepatotoxicity after a very brief course of rosuvastatin in a statin-naive patient.